Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care

Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…

AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.


CD33‑targeted transplant and post‑transplant maintenance

MRD: Beyond Morphologic Remission and the Questions That Remain

6 wks / oncodaily

John DE VOS: A New Article on Anti-CD33 CAR-T Cells Against Normal Hematopoiesis

7 wks / oncodaily

Amer Zeidan: EHA 2026 Presentation Explores HSCT Outcomes in TP53-Aberrant Neoplasms

7 wks / oncodaily

Gene-edited stem cell transplant shows promise for aggressive blood cancers

1 month / medicalxpress


Safety and ethical scrutiny of gene editing and gene therapy

Sanam Loghavi: Our Myeloid Sarcoma Paper is Out Today

7 wks / oncodaily

A rare case of gene therapy-linked cancer

7 wks / nature / Karen O’Leary

Fetal gene therapy's progress calls into question the taboo on embryo editing

7 wks / endpoints / Ryan Cross


Scaling cell therapy: accreditation and expanding CAR indications

175 facilities with cell therapy accreditation

7 wks / beckershospitalreview / Elizabeth Gregerson

168 facilities with cell therapy accreditation

7 wks / beckershospitalreview / Elizabeth Gregerson

Resetting autoimmune disease with CAR cell therapies

7 wks / nature / Georg Schett


All Other Stories

EMA Recommends Extending Indications for Decitabine / Cedazuridine

6 wks / esmo

Unveiling the novel role of PGAM5 in rewiring metabolism through PI3K/AKT/mTOR signaling in acute myelogenous leukemia

6 wks / nature

3D-printed lymph nodes could widen access to CAR T-cell therapy

6 wks / newscientist

Treatment of Shiga toxin–producing E. coli infection by CRISPR-Cas–targeted cleavage of the Shiga toxin gene in animal models

6 wks / science / Matthieu Galtier, Antonina Krawczyk, Fabien J. Fuche, Loïc H. Charpenay, Igor Stzepourginski, Simone

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma

6 wks / science / Adam S. Sperling, Benjamin A. Derman, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Nina Orwi

Coordinated regulation using small-molecule drugs enables controlled therapeutic genome editing and enhanced genomic precision in situ

6 wks / science / Ju Zhang, Li Chen, Xingyu Zhu, Yushan Cai, Shixian Wei, Xujiao Zhou, Yongshi Shi, Chuancheng Liu, Ch

Ivy Riano: Mental Health Disorders and Lower CRS Risk in CAR-T/BiTE Therapy

6 wks / oncodaily

Talha Badar: Optimizing Venetoclax Duration in AML

6 wks / oncodaily

One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible.

6 wks / nytimes / Gina Kolata

FDA approves Inqovi for acute myeloid leukemia

6 wks / medicalxpress

Naoto Ueno: NIH R01 Funds Novel Antibody–Drug Conjugate Development for Cancer Therapy

6 wks / oncodaily

Alice Lin Pomponio: Challenges and Prospects for Cellular Cancer Therapies

6 wks / oncodaily

Yan Leyfman: AI is Now Helping Redesign the Molecular Machinery Behind Genome Editing Itself

6 wks / oncodaily

Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care

1 month / nature / Paul W. Franks




Related Stories

CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 7 days

Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 6 wks

Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 8 hrs

Ten‑year follow‑up shows durable remissions with CD19 CAR‑T therapy / 14 days

Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 5 wks

Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Nutrition, Weight Loss, Price Transparency and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.